Search

Your search keyword '"Li, Ziyi"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Li, Ziyi" Remove constraint Author: "Li, Ziyi" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
84 results on '"Li, Ziyi"'

Search Results

1. Supplemental Table 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

2. Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

3. Supplemental Table 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

4. Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

5. Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

6. Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

7. Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

8. Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

9. Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

10. Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

11. Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

12. Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

13. Data from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

14. Supplemental Figure 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

15. Supplemental Figure 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

16. Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

17. Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

18. Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax

21. Supplementary Figure from SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

22. Data from SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

30. Data from SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

38. Supplementary Figure from SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

41. Data from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

42. Data from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

43. Table S1 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

44. Supplementary Figures from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

45. Table S6 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

46. Table S7 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

47. Table S7 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

48. Table S5 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

49. Supplementary Figures from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

50. Table S3 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Catalog

Books, media, physical & digital resources